Anthropic is launching its own drug discovery programs for rare diseases using Claude superintelligence. But will Big Pharma co-opt this technology to create more lifelong customers? The answer depends on who controls the feedback loops

Anthropic is launching its own drug discovery programs for rare diseases using Claude superintelligence
newstarget.com

Anthropic is launching its own drug discovery programs for rare diseases using Claude superintelligence

The news landed like a thunderclap in a San Francisco conference room on June 30, 2026. Anthropic, the artificial intelligence company behind the cutting-edge Claude model, announced it will launch its own preclinical drug-discovery programs targetin